Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500% in early trading, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - Resumption of Trading - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - Financial Performance and Compliance - The company has published all outstanding financial results and addressed any audit revisions, ensuring compliance with regulatory requirements [1] - Business Viability - TATA Health confirmed that its business operations are sustainable, with sufficient operational capacity and valuable assets to support ongoing business activities [1] - Internal Controls - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]
港股异动 | TATA健康(01255)时隔逾1年半复牌 早盘股价飙升超500%